1. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC

2. Program Goals

3. Discussion Overview

4. Overall Landscape Today: Still Rapidly Evolving

5. Where Are We in 2015?

6. Docetaxel in Hormone Treatment-Naive Disease

7. The Expanding Role of Abiraterone and Enzalutamide

8. How to Choose Between Abiraterone and Enzalutamide?

9. St Gallen Advanced Prostate Cancer Consensus Conference (APCCC 2015)

10. A Major Metabolite of Abiraterone in Humans Is a Potent AR Antagonist

11. Other Clinical Considerations for Abiraterone and Enzalutamide

12. Steroid Switch Results in Durable Responses

13. Other Therapeutic Options for mCRPC

14. Local Recurrence Symptoms Becoming an Increasing Problem

15. State of the Art Treatment for mCRPC: Recommendations

16. Clinical Genomics of Advanced Prostate Cancer: AR Pathway Aberrations

17. PI3K Pathway Aberrations in mCRPC

18. What Is the Meaning of All of This? CRPC Remains AR-Driven

19. What About PI3K/AKT Signaling? We May Also Need to Block AKT

20. DNA Repair Aberrations

21. Olaparib in mCRPC: Phase 2 TOPARP Trial

22. Olaparib in mCRPC: Results

23. Conclusions

24. Abbreviations

25. Abbreviations (cont)